This page collects WhisperX intelligence signals tagged #Merck. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
Merck is making a major strategic move to fortify its oncology portfolio, announcing its intent to acquire Terns Pharmaceuticals for $6.7 billion. The deal, priced at $53 per share, represents a 6% premium over Terns' recent closing price and centers on the promising leukemia drug TERN-701. Terns' stock had already sur...
Eli Lilly's chief dealmaker, Jake van Naarden, is operating at an intense pace, signaling a potential surge in strategic activity that could reshape the biopharma landscape. His relentless schedule is a key indicator of the competitive pressure and capital deployment underway at one of the industry's most influential p...
At the American Association for Cancer Research (AACR) annual meeting, a bold and potentially controversial clinical strategy is taking center stage. Investigators from the Dana-Farber Cancer Institute presented early-phase data showing a deep response when using the CAR-T therapy Carvykti to treat patients with smolde...